All companies

Speciality Plastics

West Pharmaceutical Services

Broader sector NYSE: WST
Headquarters
Exton, PA, US
Segment
Speciality Plastics
Stories held
3
Last story
6 Nov 2026

West Pharmaceutical Services makes components and systems for injectable drug packaging and delivery, including elastomer stoppers, seals, self-injection devices and containment solutions, and offers contract manufacturing services to pharmaceutical and biotech customers. The group is headquartered in Exton, Pennsylvania, and operates manufacturing sites across the Americas, Europe and Asia, with annual revenue above USD 2.8bn.

3 stories · 2026

West Pharmaceutical Services raises 2026 sales guidance after Q3 results

West Pharmaceutical Services reported third quarter 2026 sales of USD 874.5m and net income of USD 214m. The maker of pharmaceutical packaging and delivery components raised its full year 2026 net sales guidance to USD 3.41bn-3.42bn, with diluted EPS guidance of USD 9.31-9.41, and lifted its fourth quarter dividend. The company also completed USD 685.26m of share repurchases under its 2026 buyback programme.

Why this mattersRaised full-year guidance at a leading maker of pharmaceutical packaging and delivery components indicates firm demand from drug producers for its containment products.

  • Q3 2026 sales were USD 874.5m with net income of USD 214m
  • Full year 2026 net sales guidance raised to USD 3.41bn-3.42bn
  • Diluted EPS guidance raised to USD 9.31-9.41
  • The company completed USD 685.26m of share repurchases under its 2026 buyback programme
  • A higher fourth quarter dividend was announced alongside the guidance increase
  • Nine month 2026 revenue was USD 2.59bn and net income USD 506.8m
West Pharmaceutical Services
Relevant to you?

Gerresheimer expects Primary Packaging Plastics sale to close in Q1 2027; Q3 revenue up 8%

Gerresheimer reported preliminary third-quarter 2026 revenue of EUR 605m, up 8% year on year. Adjusted EBITDA was EUR 103m against EUR 106m, and the margin fell to 17.1% from 19.0%. After completing the Centor sale in October, Gerresheimer now expects its Primary Packaging Plastics sale to close in the first quarter of 2027. It targets nearly EUR 700m of debt repayment by year-end and expects leverage of about 3x adjusted EBITDA after both disposals. Full-year guidance was maintained.

Why this mattersDisposal proceeds are funding close to EUR 700m of debt repayment, cutting leverage to about 3x, while margins slip slightly despite 8% revenue growth.

  • Q3 2026 revenue was EUR 605m, up 8% year on year, with growth in all three segments.
  • Q3 2026 adjusted EBITDA was EUR 103m, a 17.1% margin, down EUR 3m year on year.
  • Nine-month 2026 revenue was about EUR 1.7bn with adjusted EBITDA of EUR 272m.
  • Centor sale completed in October 2026; the Primary Packaging Plastics sale is now expected to close in the first quarter of 2027.
  • Nearly EUR 700m of debt is targeted for repayment by year-end; leverage is expected to fall to about 3x adjusted EBITDA after both disposals.
  • Full-year guidance maintained at EUR 2.3bn to EUR 2.35bn revenue, 17% to 18% organic adjusted EBITDA margin, and negative EUR 50m to EUR 100m free cash flow before M&A.
  • Gross debt stood at just under EUR 2.3bn before the Centor and Primary Packaging Plastics disposals, with a path to below EUR 900m after both close.
  • Gerresheimer closed its Chicago Heights, Illinois moulded-glass plant in September 2026.
Gerresheimer West Pharmaceutical Services mentioned Centor Stevanato Group mentioned
Relevant to you?

West Pharmaceutical Services raises quarterly dividend 18%

West Pharmaceutical Services declared a fourth-quarter dividend of USD 0.26 per share, up 18% from USD 0.22 in the prior quarter. The payment, the company's 34th consecutive annual dividend increase, is payable on 18 November 2026 to shareholders of record on 11 November 2026.

Why this mattersAn 18% rise, the 34th consecutive annual increase, points to continued cash generation at a leading supplier of injectable drug containment components.

  • Dividend declared 19 October 2026 at USD 0.26 per share, up from USD 0.22 in the prior quarter.
  • This marks the 34th consecutive annual dividend increase for West Pharmaceutical Services.
  • Payable 18 November 2026 to shareholders of record as of 11 November 2026.
  • West reported USD 3.07bn in net sales for fiscal year 2025.
  • The company operates 50 sites including 26 manufacturing facilities worldwide.
West Pharmaceutical Services
Relevant to you?